Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...

October 09, 2024, 6:27 PM ESTCommercial Real Estate July 18, 2024, 9:37 AM ESTHealth Care March 06, 2024, 2:50 PM ESTHealth Care June 16, 2022, 4:42 PM ESTHealth Care May 18, 2021, 3:28 PM ...

It has shifted commercial manufacturing off Genentech's South San Francisco campus, cut hundreds of jobs, broken up its cancer immunology group and pared programs. The company, which employs about ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

On December 6, 1994, outside of the South San Francisco headquarters of a biotechnology company called Genentech, a group of protestors shouted, honked, waved signs, and laid out on the street.

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft ...

Why are Genentech’s cancer researchers concerned about the direction of the company? What led Pfizer to pull its sickle cell drug off global markets? And what cake did Adam make for all his ...

Genentech disclosed in regulatory filings this week that it will lay off 436 employees at its South San Francisco ...

A $1.2 billion deal by Swiss biotech firm Lonza to purchase the Vacaville Genentech site from Roche has been finalized, the firm announced Tuesday, securing 750 biotech jobs in Vacaville.

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in ...